Format

Send to

Choose Destination
Cell Oncol (Dordr). 2015 Oct;38(5):327-39. doi: 10.1007/s13402-015-0236-6. Epub 2015 Aug 29.

NF-κB signaling in cancer stem cells: a promising therapeutic target?

Author information

1
Epigenetics Laboratory, National Institute of Genomic Medicine, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City, 14610, Mexico.
2
Functional Cancer Genomics laboratory, National Institute of Genomic Medicine, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico, Mexico City, 14610, Mexico.
3
Epigenetics Laboratory, National Institute of Genomic Medicine, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City, 14610, Mexico. vmaldonado@inmegen.gob.mx.

Abstract

BACKGROUND:

Cancer stem cells (CSCs) are regulated by several signaling pathways that ultimately control their maintenance and expansion. NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) forms a protein complex that controls DNA transcription and, as such, plays an important role in proliferation, inflammation, angiogenesis, invasion and metastasis. The NF-κB signaling pathway, which has been found to be constitutively activated in CSCs from a variety of cancers, participates in the maintenance, expansion, proliferation and survival of CSCs. Targeted disruption of this pathway may profoundly impair the adverse phenotype of CSCs and may provide a therapeutic opportunity to remove the CSC fraction. In particular, it may be attractive to use specific NF-κB inhibitors in chronic therapeutic schemes to reduce disease progression. Exceptional low toxicity profiles of these inhibitors are a prerequisite for use in combined treatment regimens and to avoid resistance.

CONCLUSION:

Although still preliminary, recent evidence shows that such targeted strategies may be useful in adjuvant chemo-preventive settings.

KEYWORDS:

Cancer stem cells; NF-κB signaling

PMID:
26318853
DOI:
10.1007/s13402-015-0236-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center